New nerve block or drug: which eases pain after pituitary surgery?
NCT ID NCT06639659
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two approaches—a nerve block and a sedative drug—to reduce pain and improve the surgical field during trans-nasal endoscopic pituitary surgery. About 69 adults will be randomly assigned to receive either a sphenopalatine ganglion block, dexmedetomidine, or standard general anesthesia. The goal is to see which method provides better pain relief and less bleeding during and after surgery.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- sphenopalatine ganglion block (nerve block procedure) and dexmedetomidine (drug)
- What this could lead to
- If successful, this could point to a better way to manage pain and reduce bleeding during pituitary surgery, improving recovery and comfort.
- What could go wrong
- This is a small, early-stage trial with only 69 participants, so results may not apply to everyone. Both methods have risks, such as side effects from the drug or complications from the nerve block.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 69 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2024
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age: between 21-64 years old. * sex: males and females. * Body mass index: 35 kg/m2. * ASA Physical status: grade Ⅰ-Ⅱ. Exclusion Criteria: * patients receiving beta blockers, anti-coagulants and antihypertensive medications also patients receiving clonidine or benzodiazepines, neuroleptics or antidepressants two weeks prior to the study. * Any contraindication for regional anesthesia e.g. coagulopathy, infection at site of block and hypersensitivity to any drug used in this study. * Patients who are known to be drug addict.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pituitary tumor are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zagazig Univesity Hospital
Zagazig, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a recovery checklist speed healing after brain tumor surgery?
- A simple eye-tracking test may replace button-pressing exams for pituitary tumor patients
- Immunotherapy combo shows promise for tough pituitary tumors
- Scientists map immune cells in pituitary tumors to unlock new treatments
- How do patients feel after Nose-Based brain surgery? new study aims to find out
- Nerve block could make brain tumor surgery safer and less painful